Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

Alpine Immune Sciences, Inc. ALPN, a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in March.

Cowen and Company 39th Annual Health Care Conference

Date: Tuesday, March 12, 2019

Time: 9:20 a.m. Eastern Time

Location: Boston, MA

Oppenheimer 29th Annual Healthcare Conference – Analyst-Led Fireside Chat

Date: Tuesday, March 19, 2019

Time: 1:35 p.m. Eastern Time

Location: New York, NY

A live webcast of each presentation will be available online in the investor relations section of the company's website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients' lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. ALPN-101 is in a Phase I healthy volunteer trial with data expected to be reported later in 2019. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation – an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005118/en/